Thu, May-17-18, 10:20
|
|
Senior Member
Posts: 14,682
|
|
Plan: EpiPaleo/Primal/LowOx
Stats: 220/130/150
BF:
Progress: 129%
Location: USA
|
|
UPDATE:
Comment from someone on another board.
Quote:
A bit late, perhaps, but worth noting: this is the opposite of what the actual analyst suggests. The linked article asserts that’s what the analyst suggests, but is wrong – either accidentally or intentionally misreading. I’ve read the actual analysis, and what the analyst actually suggested is to be able to cure more than one disease. The analyst says that focusing on a single cure may be financially risky, that a company that develops a cure should not rest on its laurels and should already be working on the next cure.
This is not a minor detail; it’s a completely opposite moral statement. “Cure more diseases faster”, not “stop curing diseases”.
|
|